Sportradar Group AG
No enriched coverage for $SRAD in the last 7 days.
No SEC Form 4 filings for $SRAD in the last 30 days.
See all $SRAD insider activity →According to FactSet, 21 analysts reduced Sportradar Group AG’s average 12-month price target to $18.51 from $18.69. Targets range from $14.05 to $38.17 per share. With the Aug. 7 close as the reference, the revised target implies about 42% upside. The consensus rating remains “Buy” (16 Buys, 7 Holds, 0 Sells).
European gambling stocks were mixed in the week to 7 Aug 2026. Sportradar fell 10.45% after cutting full-year guidance; Q2 revenue rose 19% to €378m but it swung to a €4m loss. Flutter dropped 9.31% after a $296m quarterly loss and guidance cuts. Rank rose 6.20% and Evolution gained 1.04% on buybacks.
Simply Wall St highlighted Sportradar Group (SRAD) after its Q2 and six-month results showed higher sales but a shift from net income to net loss. The stock closed at $13.02, down 44.17% YTD. A “fair value” narrative cites $21.38 per share, while a multiples view notes SRAD trades at 2.4x P/S versus 1.5x fair.
Recent SRAD coverage spans financial news, market movers and earnings.
According to FactSet, 21 analysts reduced Sportradar Group AG’s average 12-month price target to $18.51 from $18.69. Targets range from $14.05 to $38.17 per share. With the Aug. 7 close as the reference, the revised target implies about 42% upside. The consensus rating remains “Buy” (16 Buys, 7 Holds, 0 Sells).
Lower full-year revenue and EBITDA guidance signals weaker US momentum and delays in monetization, pressuring estimates.
The article frames SRAD as potentially undervalued on sales multiples despite a loss swing, implying valuation sensitivity to margin and growth expectations.
Sportradar said on its Q2 earnings call it is expanding into US prediction markets via partnerships with Kalshi and Polymarket, aiming to grow its addressable market and diversify sportsbook clients. Management cited regulatory uncertainty and slower contract closures, pushing major financial benefits to 2027+. It reported €64m ($73.9m) revenue in SportsContent, Technology & Services, up 9% YoY, and expects 2026 full-year revenue growth of 19% to 21% (€1.518-€1.533b).
Sportradar Group AG reported a Q2 2026 net loss of €3.5 million, reversing a €49.1 million profit a year earlier, despite 18.9% year-over-year revenue growth to €378 million. The company cited higher sports-rights costs and an unrealized FX loss of about €9 million. It also trimmed full-year 2026 revenue guidance and shares fell nearly 20% premarket.
alphai scores every news story that mentions SRAD with an AI model for sentiment and relevance, and aggregates insider trades from Sportradar Group AG's SEC EDGAR Form 4 filings. Figures refresh continuously.
According to FactSet, 21 analysts reduced Sportradar Group AG’s average 12-month price target to $18.51 from $18.69. Targets range from $14.05 to $38.17 per share. With the Aug. 7 close as the reference, the revised target implies about 42% upside. The consensus rating remains “Buy” (16 Buys, 7 Holds, 0 Sells).
1 min readEuropean gambling stocks were mixed in the week to 7 Aug 2026. Sportradar fell 10.45% after cutting full-year guidance; Q2 revenue rose 19% to €378m but it swung to a €4m loss. Flutter dropped 9.31% after a $296m quarterly loss and guidance cuts. Rank rose 6.20% and Evolution gained 1.04% on buybacks.
7 min readSimply Wall St highlighted Sportradar Group (SRAD) after its Q2 and six-month results showed higher sales but a shift from net income to net loss. The stock closed at $13.02, down 44.17% YTD. A “fair value” narrative cites $21.38 per share, while a multiples view notes SRAD trades at 2.4x P/S versus 1.5x fair.
6 min readSportradar said on its Q2 earnings call it is expanding into US prediction markets via partnerships with Kalshi and Polymarket, aiming to grow its addressable market and diversify sportsbook clients. Management cited regulatory uncertainty and slower contract closures, pushing major financial benefits to 2027+. It reported €64m ($73.9m) revenue in SportsContent, Technology & Services, up 9% YoY, and expects 2026 full-year revenue growth of 19% to 21% (€1.518-€1.533b).
6 min readSportradar Group AG reported a Q2 2026 net loss of €3.5 million, reversing a €49.1 million profit a year earlier, despite 18.9% year-over-year revenue growth to €378 million. The company cited higher sports-rights costs and an unrealized FX loss of about €9 million. It also trimmed full-year 2026 revenue guidance and shares fell nearly 20% premarket.
6 min readUBS downgraded Sportradar Group to Neutral from Buy and cut its price target to $16 from $30, according to UBS. The change reflects UBS’s updated view of the stock’s valuation and outlook, which may affect investor expectations and trading sentiment for Sportradar shares.
2 min readUBS downgraded Sportradar Group AG (SRAD) to Neutral from Buy and cut its fiscal 2026 price target to $16 from $30. The move followed Sportradar reducing midpoint guidance, including €44m lower revenue and €31m lower EBITDA. UBS cited weaker margin improvement and timing of sports rights expense recognition.
6 min readSportradar Group AG (SRAD) shares fell 16.5% to $12.14 on Monday after the company reported higher Q2 and first-half revenue but net losses in both periods. Q2 revenue rose to EUR 377.8m from EUR 317.8m, while net loss was EUR 3.5m. H1 revenue increased to EUR 724.3m, with net loss of EUR 9.8m.
2 min readAnalyst notes cover Churchill Downs, MGM, Sportradar and Macau gambling. Truist says Churchill Downs’ Derby 2027 outlook and M&A plans support stable fundamentals and keeps a Buy. Texas Capital cuts MGM 2026/27 EBITDA forecasts and lowers its price target to $54. Jefferies flags Sportradar 2Q results up 19% YoY but pressured by FX and guidance. J.P. Morgan cites Macau July GGR of MOP 20.3B, down 8% YoY.
4 min readUS stock index futures rose in premarket as oil fell and bond yields eased, helped by reports of US-Iran talks. S&P futures were up 0.5% and Nasdaq up 0.4%, with Mag 7 mostly higher. Notable movers included ATKR +27% on Prysmian’s $95/share bid, BMY +5% on AstraZeneca acquisition talks, and SRAD -14% after guidance cut.
7 min read
